Is IV Ketorolac an Antipyretic?
Yes, intravenous ketorolac has antipyretic properties, though this is not its primary indication or most prominent clinical effect.
Evidence from Drug Labeling and Guidelines
The FDA label for ketorolac does not list antipyretic activity as an indication—it is approved solely for short-term (≤5 days) management of moderately severe acute pain requiring opioid-level analgesia 1. However, the pharmacodynamic profile confirms that ketorolac, like other NSAIDs, inhibits prostaglandin synthesis, which is the mechanism underlying both analgesic and antipyretic effects 1.
The 2024 BMJ guideline on ICU pain management explicitly acknowledges ketorolac's dual properties in its pharmacological comparison table, noting that acetaminophen provides "added antipyretic effects" as a distinguishing feature, implicitly confirming that ketorolac (listed separately) does possess antipyretic activity but this is not its primary clinical advantage 2.
Research Evidence Supporting Antipyretic Activity
The strongest clinical evidence comes from a 2004 double-blind, placebo-controlled trial demonstrating that IV ketorolac (0.5 mg/kg, max 30 mg) produced statistically significant temperature reduction in febrile adults 3. At 60 minutes, ketorolac reduced temperature by 0.8°C compared to 0.4°C with placebo, with an odds ratio of 7.1 for achieving afebrile status. This directly confirms antipyretic efficacy in the clinical setting.
A 1994 endotoxin-induced fever model study further validated this effect, showing that 30 mg IM ketorolac demonstrated approximately equivalent antipyretic activity to 650 mg oral acetaminophen, with statistically significant dose-response across ketorolac doses (15,30,60 mg) 4.
Multiple pharmacology reviews from 1990-1992 consistently describe ketorolac as having "analgesic, anti-inflammatory, and antipyretic properties" 5, 6, 7, and a 2025 review reaffirms it exhibits "moderate antipyretic and anti-inflammatory properties, as well as potent analgesic effects" 8.
Clinical Context and Caveats
While ketorolac does have antipyretic effects, this is not why you should prescribe it. The drug's primary role is pain management, and its use is severely restricted by:
- Maximum 5-day duration due to serious adverse event risks 1
- Contraindications including active peptic ulcer disease, recent GI bleeding, advanced renal impairment, bleeding disorders, and perioperative CABG surgery 1
- Black box warnings for GI bleeding/perforation, cardiovascular thrombotic events, renal toxicity, and bleeding risk 1
If your goal is fever reduction, acetaminophen or other NSAIDs (ibuprofen) are safer first-line choices with better safety profiles for prolonged use 2. Ketorolac should be reserved for situations where you need both potent analgesia AND fever reduction in the acute setting (e.g., postoperative patients with pain and fever), and only when contraindications are absent.
The antipyretic effect peaks at 2-3 hours, similar to its analgesic timeline 1, making it reasonable for acute fever management when already indicated for pain control, but never as a standalone antipyretic agent given its risk profile.